IRCT2015012620818N1已完成未知
Comparison the efficacy of Deferoxir versus other desferoxamine products in thalassemia major patient
exir pharmacutical company0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients with major thalassemia under regular blood injection therapy;. age over 5; undergoing treatment with one of deferoxamine pharmaceutical products; Norma renal function; serum cratinine undr 0. 7; in children under the age of 12 less than 1.0; in teenagers less than 1.1; and in over 16 years old pateinets (female less than 1.2; male less than 1.2); Trans aminase enzymes level less than 2 times of normal range; BUN<22mg/dl.
排除标准
- •Any experience of allergic reaction to desferoxamine, positive HCV Ab / HBS Ag.
研究者
相似试验
已完成
3 期
Compare the efficacy of combination therapy of Deferasirox and Deferiprone in reducing iron load in patients with transfusion-Dependent ß-Thalassemia.transfusion-Dependent ß-Thalassemia.Beta thalassemiaIRCT20190106042262N1Esfahan University of Medical Sciences108
招募中
不适用
Efficay comparison two oral chelators combination in patients with beta-thalassemiaIRCT20160310026998N7Tabriz University of Medical Sciences54
已完成
2 期
Effect of Osveral on iron overload in beta thalassemia major patients.beta thalassemia.beta thalassemiaIRCT2015102524679N2Investigator69
已完成
Unknown
Comparison of Deferazirox and Deferoxamine on Serum Ferritin Levels Changes in Major Beta Thalassemia PatientsIRCT20190817044550N4Birjand University of Medical Sciences45
尚未招募
2 期
Efficacy and safety of triple iron chelator (deferoxamine, deferasirox, and deferiprone) versus dual iron chelator (deferoxamine and deferasirox) combination therapy for reducing iron overload in transfusion-dependent beta-thalassaemia with very high iron overload.ThalassaemiaSLCTR/2023/010Prof Anuja Premawardhena